33 results
10-Q
2024 Q1
IMCR
Immunocore Holdings plc
8 May 24
Quarterly report
7:00am
expense
Research and development, or R&D, expenses consist primarily of costs incurred for current or planned investigations undertaken … and share-based compensation expense for the various R&D departments, costs associated with clinical trial activities undertaken by contract research
10-K
2023 FY
IMCR
Immunocore Holdings plc
28 Feb 24
Annual report
7:33am
forward and utilization against future operating profits.
As a company that carries out extensive research and development, or R&D, activities, we … benefit from the U.K. R&D tax relief programs, historically being the Small and Medium-sized Enterprises R&D tax relief program, or SME Program
6-K
EX-99.2
IMCR
Immunocore Holdings plc
7 Nov 23
Current report (foreign)
7:09am
.
Amendments to the U.K. R&D tax credit regime have recently been enacted, proposed or are under consultation. These amendments (amongst other things) (i … and may (unless limited exceptions apply) introduce restrictions on the tax relief that can be claimed for expenditure incurred on sub-contracted R&D activities
8-K
EX-99.1
IMCR
Immunocore Holdings plc
28 Feb 24
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
4:19pm
, as we continued our commercialization efforts.
For the fourth quarter and year ended December 31, 2023, our research and development (R&D) expenses were … and associated staff costs, increases related to consumables and facilities costs, and decreased R&D tax credits due to us no longer qualifying
8-K
IMCR
Immunocore Holdings plc
29 Jan 24
Immunocore Announces Proposed Convertible Senior Notes Offering
5:06pm
and development (“R&D”) expenses and selling, general and administrative (“SG&A”) expenses will increase when compared to such expenses for the third quarter … of 2023. The increases in R&D expenses and SG&A expenses described do not include unrealized foreign exchange losses on the translation of monetary
6-K
EX-99.2
we9gerpct una8
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.2
5xiglrvvsak
10 May 23
Current report (foreign)
7:27am
6-K
EX-99.3
afgvu17g
10 Nov 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:01am
8-K
EX-99.2
mbfi gab77l6o
28 Feb 24
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
4:19pm
6-K
EX-99.3
nshbq4y 5gyoxthtd6
11 May 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:08am
6-K
EX-99.4
pevz9m6rbex4f 3dadl
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.4
igqcr5
10 Aug 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
8:00am
6-K
EX-99.1
qmy7df xs2iaeh88
7 Nov 23
Current report (foreign)
7:09am
6-K
EX-99.1
ss01pdhhxudksubx
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.1
mp6yzgpd4wvvdancpp
3 Jun 22
Sanofi will evaluate KIMMTRAK in combination with SAR444245 as part of its ongoing Phase 1 study in advanced unresectable or metastatic skin cancers
4:05pm
6-K
EX-99.2
k42zr nsmd
11 Aug 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:00am
6-K
EX-99.2
779icfbw 43q
10 Nov 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:01am
6-K
EX-99.1
0ee5fhz
3 Mar 22
Immunocore Reports Full Year 2021 Financial Results
7:01am
6-K
EX-99.1
akx hny0yp7w54cv
10 May 23
Current report (foreign)
7:27am
6-K
EX-99.2
hxzahutdg uaos1u
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am